1015 Capital Partners’s Repligen RGEN Stock Holding History

1015 Capital Partners’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29	Closed	-$4.75K	–	623
2025 Q4	$4.75K	Buy	+29	New	+$4.54K	﹤0.01%	252

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

1015 Capital Partners's RGEN Position: Q1 2026 in Review

1015 Capital Partners sold out of Repligen (RGEN) in Q1 2026, closing a stake of 29 shares — an estimated $4.75K sold.

1015 Capital Partners first reported a position in RGEN in Q4 2025 and held it in 1 quarter. The position peaked at $4.75K in Q4 2025. 443 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

1015 Capital Partners reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
1015 Capital Partners sold 29 Repligen shares in Q1 2026, an estimated $4.75K.
1015 Capital Partners first reported a position in Repligen in Q4 2025 and held it in 1 quarter.
1015 Capital Partners's Repligen position peaked at $4.75K in Q4 2025.
443 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on 1015 Capital Partners's 13F filing for Q1 2026, filed 11 May 2026.